Literature DB >> 20190159

Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I.

Alexander T Faje1, Ariel L Barkan.   

Abstract

CONTEXT: Previous studies have shown that mean 24-h GH concentrations determine plasma IGF-I levels in patients with acromegaly. However, we have recently shown that continuous GH infusion, mimicking the interpulse GH levels, was significantly more effective than the pulsatile GH administration at increasing IGF-I concentrations.
OBJECTIVE: The aim of the study was to ascertain relative roles of total GH output (24-h mean), GH pulses, and interpulse GH level in determining plasma IGF-I concentrations. DESIGN AND
SETTING: We conducted a point-in-time observational inpatient study in the General Clinical Research Center at the University of Michigan. PATIENTS OR OTHER PARTICIPANTS: Eighteen patients with acromegaly and 19 healthy control subjects participated in the study. INTERVENTION(S): We performed frequent (every 10 or 20 min) blood sampling over 24 h. MAIN OUTCOME MEASURE(S): Before data collection, we hypothesized that interpulse nadir levels of GH would correlate with IGF-I levels in normal and acromegalic subjects.
RESULTS: Mean and valley levels of GH correlated with serum IGF-I levels (r(2) = 0.44 and 0.48, respectively) in normal and acromegalic patients in a log-linear fashion. The strongest correlation, however, was observed between the log of nadir GH and IGF-I concentrations (r(2) = 0.77). GH pulse mass did not significantly correlate with IGF-I (r(2) = 0.001).
CONCLUSIONS: Plasma IGF-I concentrations correlated with mean 24-h GH concentrations. This relationship is dependent exclusively on the basal GH levels. GH pulses do not determine plasma IGF-I concentrations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190159      PMCID: PMC2869549          DOI: 10.1210/jc.2009-2634

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

Review 1.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline.

Authors:  Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Stephen M Shalet; Mary Lee Vance; Patricia A Stephens
Journal:  J Clin Endocrinol Metab       Date:  2006-04-24       Impact factor: 5.958

Review 2.  Gender differences in secretory activity of the human somatotropic (growth hormone) axis.

Authors:  J D Veldhuis
Journal:  Eur J Endocrinol       Date:  1996-03       Impact factor: 6.664

3.  Effects of pulsatile delivery of basal growth hormone on lipolysis in humans.

Authors:  E Cersosimo; F Danou; M Persson; J M Miles
Journal:  Am J Physiol       Date:  1996-07

4.  A sexually dimorphic pattern of growth hormone secretion in the elderly.

Authors:  P C Hindmarsh; E Dennison; S M Pincus; C Cooper; C H Fall; D R Matthews; P J Pringle; C G Brook
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

5.  Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy.

Authors:  M L Hartman; J D Veldhuis; M L Vance; A C Faria; R W Furlanetto; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

6.  Regulatory mechanisms of growth hormone secretion are sexually dimorphic.

Authors:  C A Jaffe; B Ocampo-Lim; W Guo; K Krueger; I Sugahara; R DeMott-Friberg; M Bermann; A L Barkan
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

7.  The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects.

Authors:  Sowmya Surya; Jeffrey F Horowitz; Naila Goldenberg; Alla Sakharova; Matthew Harber; Andrea S Cornford; Kathy Symons; Ariel L Barkan
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

8.  Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation.

Authors:  C A Gebert; S H Park; D J Waxman
Journal:  Mol Endocrinol       Date:  1997-04

9.  A highly sensitive growth hormone (GH) enzyme-linked immunosorbent assay uncovers increased contribution of a tonic mode of GH secretion in adults with organic GH deficiency.

Authors:  A T Reutens; J D Veldhuis; D M Hoffman; K C Leung; K K Ho
Journal:  J Clin Endocrinol Metab       Date:  1996-04       Impact factor: 5.958

10.  Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes.

Authors:  C Liddle; B J Goodwin; J George; M Tapner; G C Farrell
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

View more
  21 in total

1.  Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults.

Authors:  Johannes D Veldhuis; Ferdinand Roelfsema; Daniel M Keenan; Steven Pincus
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

Review 2.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

3.  "Micromegaly": an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era.

Authors:  Laura B Butz; Stephen E Sullivan; William F Chandler; Ariel L Barkan
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

Review 4.  The changing face of acromegaly--advances in diagnosis and treatment.

Authors:  Antônio Ribeiro-Oliveira; Ariel Barkan
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

5.  Rapid suppression of growth hormone concentration by overeating: potential mediation by hyperinsulinemia.

Authors:  Andrea S Cornford; Ariel L Barkan; Jeffrey F Horowitz
Journal:  J Clin Endocrinol Metab       Date:  2011-01-05       Impact factor: 5.958

6.  Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

Authors:  Georgiana Dobri; Soamsiri Niwattisaiwong; James F Bena; Manjula Gupta; John Kirwan; Lawrence Kennedy; Amir H Hamrahian
Journal:  Endocrine       Date:  2018-11-10       Impact factor: 3.633

7.  Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?

Authors:  Jessica A Brzana; Chris G Yedinak; Johnny B Delashaw; Hume S Gultelkin; David Cook; Maria Fleseriu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

8.  Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.

Authors:  Yasuyuki Kinoshita; Atsushi Tominaga; Satoshi Usui; Kazunori Arita; Tetsuhiko Sakoguchi; Kazuhiko Sugiyama; Kaoru Kurisu
Journal:  Neurosurg Rev       Date:  2016-01-20       Impact factor: 3.042

Review 9.  Estrogen treatment for acromegaly.

Authors:  Ilan Shimon; Ariel Barkan
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

10.  Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity.

Authors:  Takara L Stanley; Meghan N Feldpausch; Caitlin A Murphy; Steven K Grinspoon; Hideo Makimura
Journal:  Growth Horm IGF Res       Date:  2013-11-15       Impact factor: 2.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.